Views

CrossRef citations to date

Altmetric

Original Articles

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Sarah Goldman-MazurDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland; Correspondence[email protected]

Artur JurczyszynDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland;

Jorge J. CastilloDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;

http://orcid.org/0000-0001-9490-7532

Anna Waszczuk-GajdaDepartment of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland;

http://orcid.org/0000-0001-5626-1750

Norbert GrząśkoDepartment of Experimental Hematology, Medical University of Lublin, Lublin, Poland; ;Department of Hematology, St. John’s Cancer Center, Lublin, Poland;

Jakub Radocha4th Department of Internal Medicine – Hematology, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic;

Max BittrichDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany;

Klaus Martin KortümDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany;

http://orcid.org/0000-0002-7011-0286

Alessandro GozzettiDivision of Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy;

Lidia Usnarska-ZubkiewiczDepartment of Hematology, Wroclaw Medical University, Wroclaw, Poland;

Julio D. VallsComplejo Asistencial de Avila, Avila, Spain;

David S. JayabalanWeill Cornell Medical College, New York, NY, USA;

Ruben NiesvizkyWeill Cornell Medical College, New York, NY, USA;

Julia KelmanWeill Cornell Medical College, New York, NY, USA;

Daniel CoriuDepartment of Hematology, Fundeni Clinical Institute, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania;

http://orcid.org/0000-0002-7251-6079

Laura RosiñolDepartments of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain;

http://orcid.org/0000-0001-9531-961X

Łukasz SzukalskiDepartment of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland;

Veronica González-CalleHospital Universitario de Salamanca/Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain;

María-Victoria MateosHospital Universitario de Salamanca/Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain;

http://orcid.org/0000-0003-2390-1218

Krzysztof JamroziakInstitute of Hematology and Transfusion Medicine, Warsaw, Poland;

Iwona HusDepartment of Experimental Hematology, Medical University of Lublin, Lublin, Poland; ;Department of Hematology, St. John’s Cancer Center, Lublin, Poland; ;Institute of Hematology and Transfusion Medicine, Warsaw, Poland;

Irit AviviTel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;

Yael CohenTel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;

http://orcid.org/0000-0002-9061-7287

Piotr MazurInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland;

http://orcid.org/0000-0003-4077-1232

Anna SuskaDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland;

Aimee ChappellDepartment of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, NW, USA;

Deepu MadduriIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA;

Saurabh ChhabraDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;

Ariel KlemanDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;

Parameswaran HariDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;

Michel DelforgeDepartment of Hematology, UZ Leuven, Leuven, Belgium;

Paweł RobakDepartment of Experimental Hematology, Medical University of Lodz, Lodz, Poland;

Massimo GentileHematology Unit, AO Cosenza, Cosenza, Italy;

Izabela KozłowskaDepartment of Hematology, SPZOZ ZSM, Chorzow, Poland;

Stuart L. GoldbergJohn Theurer Cancer Center, Hackensack UMC, Hackensack, NJ, USA; ;Cota Inc, Boston, MA, USA;

Jacek CzepielDepartment of Infectious and Tropical Diseases, Jagiellonian University Medical College, Cracow, Poland;

Monika Długosz-DaneckaMaria Sklodowska-Curie National Institute of Oncology, Cracow, Poland;

http://orcid.org/0000-0002-8927-4125

Rebecca SilbermannDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA;

Adam J. OlszewskiDepartment of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA;

http://orcid.org/0000-0002-6472-6658

Peter BarthDepartment of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA;

Gabor MikalaDepartment of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute of Hematology and Infectology, Budapest, Hungary;

Chor S. ChimDepartment of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong

http://orcid.org/0000-0003-2427-915X

David H. VesoleJohn Theurer Cancer Center, Hackensack UMC, Hackensack, NJ, USA;

show all

Abstract

The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients – 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).

Keywords:

Acknowledgments

The authors expressed their gratitude for all persons who were involved in reporting patients and gathering data.

Disclosure statement

The authors declare no conflict of interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Information for

Open access

Opportunities

Help and information

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Abstract

Acknowledgments

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature